Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR) announced the presentation of preclinical results characterizing TKM-HBV, a therapeutic agent targeting human hepatitis B virus (HBV), at the 10th Annual Meeting of the Oligonucleotide Therapeutics Society. Tekmira’s Chief Technical Officer, Dr. Ian MacLachlan delivered a podium presentation titled, “Update on the Preclinical Development of an LNP-Based HBV Therapeutic.” The conference was at San Diego, California, from October 12 – 15, … Continue reading Trending Tickers : Tekmira Pharmaceuticals Corp. (NASDAQ:TKMR), Monolithic Power Systems Inc. (NASDAQ:MPWR), Fleetmatics Group PLC (NYSE:FLTX), General Motors Company (NYSE:GM), Kindred Healthcare Inc. (NYSE:KND)